On June 12, 2025 Silence Therapeutics plc ("Silence" or the "Company") (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, reported additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) (Free EHA Whitepaper) 2025 Annual Meeting in Milan, Italy (Press release, Silence Therapeutics, JUN 12, 2025, View Source [SID1234653867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The latest data presented at EHA (Free EHA Whitepaper) today continue to demonstrate divesiran’s potential to maintain rapid and durable control of hematocrit and essentially eliminate the need for phlebotomies in phlebotomy-dependent PV patients," said Marina Kremyanskaya, MD, PhD, Associate Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. "These early findings also suggest the potential for infrequent dosing and continue to support a favorable safety profile. I’m very encouraged by the consistency of the Phase 1 dataset and look forward to further development."

"Divesiran continues to demonstrate a very compelling profile as the first-in-class siRNA for PV," said Craig Tooman, President and Chief Executive Officer at Silence Therapeutics. "We are extremely encouraged by the support we are garnering from the physician community and that’s reflected in the positive momentum we’re seeing in the SANRECO Phase 2 study. The Phase 2 study is over 50-percent enrolled, and we remain on-track to complete patient enrollment by the end of this year."

Summary of Updated SANRECO Phase 1 Study Results

Results included 21 phlebotomy-dependent PV patients with a combined history of 79 phlebotomies prior to dosing. Therapeutic phlebotomies were essentially eliminated and mean hematocrit (HCT) levels were lowered and maintained to ≤ 45% for all cohorts regardless of baseline levels.
Divesiran increased hepcidin and ferritin, resulting in elevation of iron body content and improved iron deficiency.
Divesiran demonstrated similar results in all patient groups, independent of baseline risk or prior and concurrent therapy.
White blood cells were not altered over the time-course of the study.
Platelets increased, reaching a plateau with no dose dependent effect.
Divesiran was well tolerated with no dose-limiting toxicities.
SANRECO Phase 1 Study Design
The Phase 1 portion of SANRECO was a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously every 6 weeks for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria included a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five in the last year prior to screening. Patients were allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 study, both well-controlled patients – defined as those with HCT levels at 45% or less – as well as those with HCT levels greater than 45% at baseline on current standard of care treatment were enrolled.

SANRECO Phase 2 Study Design
The Phase 2 portion of SANRECO is now enrolling PV patients and is a randomized, double-blind study evaluating two different divesiran regimens versus placebo. Key inclusion criteria include a PV diagnosis and a history of requiring at least three phlebotomies in the last seven months or five in the last year prior to dosing. Patients are allowed to be on stable doses of cytoreductive agents. Patients must have HCT levels less than 45% prior to dosing. For more information, please click here.

About PV
PV is a rare, myeloproliferative neoplasm – a type of blood cancer – characterized by the excessive production of red blood cells, often resulting in elevated hematocrit levels. Elevated hematocrit above 45-percent is associated with a four-times higher rate of death from cardiovascular or thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritus and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain hematocrit less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care includes repeated phlebotomies to reduce hematocrit and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and hematocrit.

About Divesiran
Divesiran is Silence’s wholly owned siRNA product candidate developed from its proprietary mRNAi GOLD platform that "silences" TMPRSS6 expressed almost exclusively in the liver. TMPRSS6 is a negative regulator of hepcidin, the body’s master regulator of iron metabolism including its absorption, distribution, and storage. By silencing TMPRSS6 in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. Divesiran is currently in Phase 2 development for PV and has FDA Fast Track and Orphan Drug designations for PV.